Financials and Shareholder Letters

Financial Year 2019

Appendix 4D and Half Year Accounts
Quarterly Update and Appendix 4C – Dec 2018
Appendix 4C – Quarterly Sep 2018

Financial Year 2018

2018 Letter to Shareholders
Annual Report 2018
Appendix 4E – Preliminary Final Report
Quarterly Update and Appendix 4C – Jun 2018
Quarterly Update and Appendix 4C – Mar 2018
Appendix 4D and Half Year Accounts
Appendix 4C – Quarterly Dec 2017
Appendix 4C – Quarterly Sep 2017

Financial Year 2017

2017 Letter to Shareholders
Annual Report 2017
Appendix 4E – Preliminary Final Report
Appendix 4C – Quarterly Jun 2017
Appendix 4C – Quarterly Mar 2017
Appendix 4D and Half Year Accounts
Appendix 4C – Quarterly Dec 2016
Appendix 4C – Quarterly Sep 2016

Financial Year 2016

2016 Letter to Shareholders
Annual Report 2016
Appendix 4E – Preliminary Final Report
Appendix 4C – Quarterly Jun 2016
Appendix 4C – Quarterly Mar 2016
Appendix 4D and Half Year Accounts
Appendix 4C – Quarterly Dec 2015
Appendix 4C – Quarterly Sep 2015

Financial Year 2015

Annual Report 2015

For a full list of company financial announcements visit the ASX website.

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

    

LEGAL
Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.